RESUMEN
Objective To investigate the effect of abdominal Bevacizumab combined with hyperthermia chemotherapy on serum transforming growth factor beta1 (TGF-β1) and macrophage migration-inhibitory factor (MIF) levels in elderly patients with ovarian cancer.Methods A hundred elderly patients diagnosed with ovarian cancer from December 2011 to December 2014 at our hospital were recruited.Participants were assigned into a joint therapy group (n =50) and a thermal therapy group (n =50) according to the received treatment.Both groups were given the abdominal hyperthermia chemotherapy treatment,while the joint therapy group was additionally given Bevacizumab treatment.The effectiveness of treatment,adverse reactions,pre-and post-treatment serum TGF-β1 and MIF levels,and the 2-year survival situation in all participants were collected and analyzed.Results The therapeutic response rate and 2-year survival rate in the joint therapy group (64.0％ and 60.0％) were significantly higher than those in the thermal therapy group (44.0％ and 40.0％) (both P ＜ 0.05).There were statistically significant differences between pre-and posttreatment levels of serum TGF-β1 [(346.15 ± 35.15) ng/L vs.(201.46 ± 23.75) ng/L] and MIF [(46.32±5.16)μg/L vs.(13.48±2.45)μg/L] in the thermal therapy group,and of serum TGF-β1 [(342.26±35.01) ng/L vs.(167.52±20.26) ng/L] and MIF [(46.97±5.24)μg/L vs.(4.87±1.02)μg/L] in the joint therapy group,with greater reductions observed in the joint therapy group (P＜0.05).No significant difference in the incidence of adverse reactions was found between the two groups (P ＞ 0.05).Conclusions Abdominal Bevacizumab combined with hyperthermia chemotherapy can effectively decrease the levels of serum TGF-β1 and MIF in elderly patients with ovarian cancer and achieve improved short-term and long-term effectiveness with good safety.
RESUMEN
Objective To evaluate the value of percutaneous hyperthermia-chemotherapy (PHC)under CT guided in treating original and secondary hepatic and pulmonary malignant tumor.Methods Percutaneous hyperthermia and chemotherapy under CT guided was performed for 21 patient with original and secondary hepatic and pulmonary malignant tumor.Chemical drugs against tumors were warmed to 55～60℃ and injected into the tumors.Injected volume was according to:V=4/3 ?(r+0.5 cm) 3.Observation depends upon attenuation changes of CT scanning and biochemical index(AFP)The therapeutic effect was classified into Ⅰ～Ⅴgrade.Results The period of observation was 36 monthes,In 20 cases,survival period was 8～22 monthes,average survival period was 16 monthes.A patient had treated with PHC and transcatheter arterial embolization and was alive for 28 monthes.Total effective rate was 95.2%.Conclusion PHC under CT guidence is an effective method in treating hepatic and pulmonary malignant tumors.especially for unresected tumors.Cooperating transcatheter arterial embolization(TAE)can raise curative effect.